Kangwei Bio is a research and development manufacturer of new anti-tumor drugs, focusing on health science project research, development, medical research, drug research and development, etc., and is committed to providing cancer treatment drugs for patients. Recently, Kangwei Bio completed the A+ round of financing of over 100 million yuan, which was exclusively invested by SDIC Ventures. The funds raised in this round are mainly used to accelerate the clinical trials of multiple projects in the R&D pipeline of Conway Bio, and will also promote the preclinical development and international cooperation of follow-up projects.
This article is reproduced from: https://www.itjuzi.com/investevent/13470608
This site is for inclusion only, and the copyright belongs to the original author.